gilead sciences yeztugo

News

FDA approves Yeztugo

Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent effectiveness in trials. Here's how it works, and what it costs.

Pharmaceutical Technology on M… · 2d

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV

This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthrou

Yahoo Finance · 3d

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg,

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Pharmabiz1d

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

Fierce Pharma3d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results